CYP2C9 and metabolic dysfunction-associated steatotic liver disease: The study by Orsini et al. (2018) found an association between CYP2C9*2 and CYP2C9*3 with the onset of non-alcoholic fatty liver disease and severe VPA-induced hyperammonemia [71].